

Biological Subtypes of Breast Cancer and Pattern of Locoregional

Darwish A^{1*}
Abdel latif A²
Abdallah D³

¹Clinical Oncology Department, Faculty of Medicine, Alexandria University, Egypt

²General Surgery Department, Faculty of Medicine, Alexandria University, Egypt

³Pathology Department, Faculty of Medicine, Alexandria University, Egypt

Abstract

Purpose: To evaluate the rate of locoregional recurrence (LRR) of breast cancer according to its biological subtype.

Methods: we retrospectively reviewed the clinicopathological data of 821 patients with stage I-III breast cancer, who undergone MRM or BCS ± adjuvant radiotherapy in a single institution. We investigated the effect of biological subtypes, determined by Estrogen receptor (ER) receptor, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status and Ki 67, on locoregional recurrence (LRR).

Results: Luminal A subtype represented 46.7% of our patients, luminal B 26.3%, luminal B/HER2 10.7 %, the HER2 positive 7.2 % and the triple negative (TN) 9.6%. Patients with Her2 positive and TN subtypes were younger than other groups (<0.001), presenting with more advanced (T₃) tumors (<0.001), more nodal involvement (0.009) and higher grade (<0.001) compared to other groups. After a median follow up of 62 months, the rate of LRR was 4.9% (41/821). Mean LRR-FS was 88 months (95% CI 84.7–90.5). The incidence of LRR differed significantly according to the biological subtype. Patients with luminal A subtype showed the lowest rate of LRR (1.6%) compared to other subtypes; 5.6% in luminal B, 6.8% in luminal B/Her2, 10.2% in Her2 positive. TNBC had the highest LRR (13.9%). In univariate analysis, younger age, increasing tumor size, nodal involvement and tumor subtype significantly predict LRR. In multivariate analysis, independent factors associated with increased LRR were tumor size and subtype.

Conclusion: According to our results, Her2 positive and TN subtypes are associated with higher LRR rate. These subtypes may need more aggressive local treatment.

Keywords: Breast cancer; Locoregional; Recurrence; Biological; Subtype

Abbreviations and Acronyms

BCT: Breast conservative treatment; DCIS: Ductal carcinoma in situ; HER2: Human epidermal growth factor 2; HR: Hazard ratio; LVI: Lympho-vascular invasion; LRR: Locoregional recurrence; LRR-FS: Locoregional recurrence free survival; TNBC: Triple negative breast cancer.

Introduction

The incidence of local-regional recurrences after surgery for breast cancer is generally low, but it adversely affects the disease free survival and overall survival [1]. It has been proved that the prevention of four local-regional recurrences should prevent one breast cancer death [2].

Article Information

Article Type: Research

Article Number: IJCT117

Received Date: 21 May, 2019

Accepted Date: 11 June, 2019

Published Date: 14 June, 2019

***Corresponding author:** Azza Darwish, Lecturer, Clinical Oncology Department (ACOD), Faculty of Medicine, Alexandria University, Champlion Street, Alazarita, Alexandria 21131, Egypt. Tel: +2 01011116092; Email: [azzadarwish2005\(at\)yahoo.com](mailto:azzadarwish2005(at)yahoo.com)

Citation: Darwish A, latif AA, Abdallah D (2019) Biological Subtypes of Breast Cancer and Pattern of Locoregional. Int J Cancer Tremnt Vol: 2, Issu: 1 (47-53).

Copyright: © 2019 Darwish A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Multiple factors are considered as important predictors of local-regional failure as tumor size, nodal status, high histologic grade, lymphovascular invasion and positive margins [3,4].

However, breast cancer with similar standard clinicopathological characteristics can still show widely variable clinical behaviors [5]. This diversity in natural history may reflect the underlying molecular biology of the disease [6,7].

Molecular subtyping confirms that breast cancer is not a single entity, but comprises at least four genetically distinct diseases based on the expression of a 496-gene “intrinsic”[8,9].

The major intrinsic breast cancer subtypes include: luminal A (HR positive, HER2 negative, low proliferative activity), luminal B (HR positive, higher proliferative activity or HER2 positive), HER2 enriched (HR negative and HER2 overexpressing tumors), and triple-negative breast cancer (TNBC) (HR and HER2 negative) [10]. Gene expression profiling suggested 14 to be the best cutoff point of KI67 to discriminate luminal A from luminal B breast cancer subtype [11].

Molecular subtypes of breast cancer have correlated with variations in recurrence rates and survival, and have been used for prognostication and tailoring of systemic

therapy [12,13] However, their role in deciding the optimal locoregional management is still controversial.

Better and deeper understanding of the pattern of local-regional recurrences across the different breast cancer molecular subtypes may improve prediction of locoregional recurrence (LRR) and may be an effective modality in tailoring the optimal local-regional treatment of each subtype.

The aim of this work was to assess the pattern of local-regional recurrence across the different molecular subtypes in patients with newly diagnosed breast cancer treated with either breast-conserving therapy or mastectomy and adjuvant radiotherapy if indicated.

Patients and Methods

We retrospectively reviewed the medical records of histologically-confirmed operable breast cancer patients treated with breast conserving therapy or mastectomy with curative intent in our institution between 2009 and 2015. We collected all the clinicopathological characteristics, treatment information and patient follow up data. We found 2,053 patients with stages I to III breast cancer. We excluded patients with metastatic breast cancer, bilateral breast cancer, carcinoma in situ and patients who received neoadjuvant chemotherapy. Patients whose follow up data or tumor samples not available, were excluded too. Finally, 821 patients met the eligibility criteria of our study (Figure




Figure 1: Flow diagram of the patients through the study. DCIS, ductal carcinoma in situ. TNBC, triple negative breast cancer.

1). We collected all the clinicopathological characteristics, treatment information and patient follow up data for the eligible patients.

Molecular subtyping is done using immunohistochemical assessment of ER & PR & Her 2 & Ki 67. For the quantitative measurement, ER- and PR-positivity was defined as $\geq 1\%$ of tumor cells showing positive nuclear staining of any intensity; negative staining was reported if the percentage of tumor cells showing staining of any intensity was $< 1\%$. A minimum of 100 tumor cells were assessed, and the percentage of tumor cell nuclei in was recorded.

Tumors were considered HER2-positive if they had a score of 3+ or 2+ on IHC and this score was confirmed with FISH. For Ki 67 nuclear positive staining was assessed, and then classified into two groups ($< 14\%$ and $> 14\%$)

For molecular typing, patients were classified into four subtypes: luminal A (ER+ or PR+, HER2-, and Ki-67 $< 14\%$); luminal B ([ER+ or PR+, HER2-, and Ki-67 $\geq 14\%$] or [ER+ or PR+ and HER2+]); HER2-enriched (ER- and PR- and HER2+); and basal-like (ER- and PR- and HER2-). This study was approved by the local Ethics Review Board.

End points and Statistical methods

The primary endpoints were LRR and LRR-free survival (LRFS)

LRR was defined as first site of failure being ipsilateral; in-breast recurrence after lumpectomy, chest wall recurrence after mastectomy, or recurrence in the ipsilateral axillary, supraclavicular, internal mammary or infraclavicular lymph

nodes that is confirmed by pathological biopsy and without any evidence of distant disease.

LRR-Free-Survival (LRR-FS) was defined as the time from surgery to the date of LRR, death due to any cause, or the last follow-up.

and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). The Kolmogorov- Smirnov test was used to verify the normality of distribution of variables, Comparisons between groups for categorical variables were assessed using Chi-square test (Fisher or MonteCarlo). ANOVA was used to compare more than two groups for normally distributed quantitative variables and followed by Post Hoc test (Tukey) for pairwise comparison. Kruskal Wallis test was used to compare different groups for not-normally distributed quantitative variables and followed by Post Hoc test (Dunn's) for pairwise comparison. Rates of LRR free survival was calculated by Kaplan-Meier method. For the multivariate analysis, Cox Regression were used. Significance of the obtained results was judged at the 5% level.

Results

Distribution of clinicopathologic characteristics between different molecular subtypes

Of 2,053 patients of the overall cohort, 821 newly diagnosed BC patients were eligible to be included in this study. The baseline clinicopathological characteristics of the eligible patients, stratified by their biological subtypes, are listed in table 1. Luminal A subtype consisted of 379 patients

Table 1: Distribution of clinicopathologic characteristics among molecular subtypes.

	Luminal A (n = 379)	Luminal B (n=216)	Luminal B/Her2 (n=88)	Her2 positive (n=59)	Triple negative (n=79)	P value
Age	56 (26-80)	59 (35-75)	55 (32-82)	47 (35-76)	51 (40-68)	< 0.001
Surgery						
BCS	95 (25.1%)	68 (31.5%)	29 (33%)	41 (69.5%)	27 (34.2%)	0.09
MRM	284 (74.9%)	148 (68.5%)	59 (67%)	18 (30.5%)	52 (65.8%)	
Histology						
IDC	341 (90%)	192 (88.9%)	78 (88.6%)	59 (100%)	78 (98.7%)	0.001
ILC	38 (10%)	24 (11.1%)	10 (11.3%)	0	1 (1.3%)	
Grade						
I	12 (3.2%)	4 (1.9%)	1 (1.1%)	0	0	< 0.001
II	355 (93.7%)	201 (93%)	70 (79.5%)	41 (69.5%)	62 (78.5%)	
III	12 (3.2%)	11 (5.1%)	17 (19.3%)	18 (30.5%)	17 (21.5%)	
T						
1	112 (29.6%)	59 (27.3%)	11 (12.5%)	5 (8.5%)	8 (10.1%)	< 0.001
2	208 (54.9%)	126 (58%)	64 (72.6%)	39 (66.1%)	48 (60.7%)	
3	35 (9.2%)	25 (11.6%)	13 (14.7%)	15 (25.4%)	17 (21.5%)	
Unknown	24 (6.3%)	6 (2.8%)	0	0	6 (6.7%)	
N						
0	166 (43.8%)	81 (37.5%)	9 (10.2%)	5 (8.5%)	5 (6.3%)	0.009
1	124 (32.7%)	67 (31%)	24 (27.3%)	23 (38.9%)	30 (38%)	
2	65 (17.2%)	42 (19.4%)	41 (46.6%)	24 (40.6%)	33 (41.8%)	
3	6 (1.6%)	7 (3.2%)	8 (9.1%)	7 (11.6%)	11 (13.9%)	
Unknown	18 (4.7%)	19 (8.8%)	6 (6.8%)	0	0	
Extranodal invasion						
No	323 (85.2%)	179 (82.9%)	72 (81.1%)	50 (84.7%)	64 (81%)	0.475
Yes	56 (14.8%)	37 (17.1%)	16 (18.2%)	9 (15.3%)	15 (19%)	

LVI			36 (40.9%)	20 (33.9%)	27 (34.1%)	
Negative	159 (42%)	78 (36%)	52 (59%)	39 (66.1%)	52 (65.8%)	0.652
positive	220 (58%)	138 (64%)				
Chemotherapy						
No	87 (23%)	44 (20.4%)	12 (13.6%)	0 (0.0%)	0 (0.0%)	
Anthracycline-based	194 (51.2%)	109 (50.4%)	41 (46.6%)	25 (42.4%)	43 (54.4%)	<0.001
Anthracycline/Taxanes	76 (20%)	47 (22.7%)	35 (39.8%)	29 (49.2%)	30 (38%)	
Unknown	22 (5.8%)	16 (7.4%)	0 (0.0%)	5 (8.5%)	6 (7.6%)	
Trastuzumab						
No	379 (100.0%)B	216 (100.0%)	57 (64.8%)	36 (61%)	79 (100.0%)	<0.001
Yes	0 (0.0%)	0 (0.0%)	19 (21.6%)	17 (28.9%)	0 (0.0%)	
Unkown	0 (0.0%)	0 (0.0%)	12 (13.6%)	6 (10.1%)	0 (0.0%)	
Hormonal therapy	0 (0.0%)	0 (0.0%)				
No	303 (79.9%)	158 (73.1%)	0 (0.0%)	59 (100.0%)	79 (100.0%)	
Tamoxifen	18 (4.7%)	18 (8.3%)	53 (60.2%)	0 (0.0%)	0 (0.0%)	<0.001
Aromatase inhibitor	53 (14.0%)	29 (13.4%)	23 (26.1%)	0 (0.0%)	0 (0.0%)	
Both	5 (1.3%)	11(5.1%)	12 (13.6%)	0 (0.0%)	0 (0.0%)	
Unknown			0 (0.0%)	0 (0.0%)	0(0.0%)	
Follow up in months	77(8–102)	66 (9–89)	43 (20–55)	43 (20–55)	40 (6–50)	<0.001

BCS: Breast Conserving Surgery

MRM: Modified Radical Mastectomy

LVI: Lymphovascular Invasion

(46.7%), luminal B subtype consisted of 216 patients (26.3 %), luminal B/HER2 subtype consisted of 88 patients (10.7 %), the HER2 subtype consisted of 59 patients (7.2 %) and the triple negative subtype consisted of 79 patients (9.6%).

Patients with luminal A, luminal B and luminal B/HER2 subtypes were significantly older than patients in the Her2 positive and TNBC subtypes ($p < 0.001$).

Most of the T₁ tumors were seen in patients with luminal A (29.6%) and luminal B (27.3%) subtypes compared to other groups, while T₃ tumors were more frequently seen in patients with Her2+ (25.4%) and TN (21.5%) subtypes, the difference was statistically significant ($p < 0.001$).

Infiltrating ductal carcinoma was the commnest histologic type in all tumor subtypes, whereas lobular cancer was more frequently identified in luminal A, luminal B and luminal B/HER2 groups.

Most of the patients in all groups had grade 2 tumors. Grade 3 tumors were significantly seen in luminal B/HER2, HER2 positive and TN tumors compared to luminal A and luminal B ($p < 0.0001$). Luminal A and luminal B had significantly lower rate of lymph nodes involvement compared to other subtypes (0.009).

Modified radical mastectomy was more frequent than breast conserving surgery, in all groups. Systemic chemotherapy was given to 76.6% of the patients. Patients with luminal A and luminal B subtypes were the least to receive systemic chemotherapy (71.2% in luminal A and 73.1% in luminal B compared with 86.4% in luminal B/Her2, 91.6% in Her2 positive, and 92.4 % in TNBC [$p < 0.001$]). In the subset of patients who received chemotherapy, Anthracycline based chemotherapy was the most to be given (65%). Trastuzumab was received by 46.6% of the patients in the Luminal B/Her2 group and 49.6% in the Her2 positive group.

Hormonal therapy was given almost to all patients with ER and or PR positive tumors. Hormonal therapy was in

the form of tamoxifen alone, aromatase inhibitors alone or sequential tamoxifen and aromatase inhibitors. Tamoxifen alone was given to 79.9% of patients with luminal A, 73.1% of patients with luminal B compared to 60.2% of patients with Luminal B/Her2. While aromatase inhibitors either alone or sequential with tamoxifen was given to 39.7% of patients with luminal B/HER2 compared to 18.7% of patients in luminal A and 21.7% of patients with luminal B ($P < 0.001$).

The period of follow up differs among the five groups, with the longest follow up identified in patients with luminal A tumors followed by luminal B, luminal B/Her2, HER2 positive and TNBC ($P < 0.001$).

Patterns of LRR by biological subtypes

After a median follow up of 62 months, the rate of locoregional recurrence was 4.9% (41/821). Mean LRR-FS was 88 months (95% CI 84.7-90.5).

The incidence of LRR differed significantly according to the biological subtype. Patients with luminal A subtype showed the lowest rate of LRR (1.6%) compared to other subtypes; 5.6% in luminal B, 6.8% in luminal B/Her2, 10.2% in Her2 positive subtype. TNBC had the highest LRR (13.9%).

The most common sites of LRR were breast and chest wall followed by regional lymph nodes. In luminal A the rate of local and regional recurrence was 1.6 % and 0.3% respectively, and this difference was statistically significant. Whereas the rate of local and regional relapse in luminal B was 4.2% and 1.4% respectively, in luminal B/Her2 was 6.8% and 3.4% respectively. HER2 positive and TNBC subtypes were associated with rate of local and regional recurrence of 6.8% and 3.4% for HER2 positive and 11.4% and 2.5% for TNBC, respectively (Table 2).

The mean LRR-FS varied across the tumor subtypes, in luminal A the mean LRR-FS was 97.1 months (95% CI 93.4–99.2), in luminal B 85.9 (95% CI 84.4-87.5), in Luminal B/




Figure 2: Molecular subtypes and locoregional-free survival.

Table 2: Locoregional recurrence in tumor subtypes.

Recurrence	Luminal A (n = 379)	Luminal B (n=216)	Luminal B/Her2 (n=88)	Her2 positive (n=59)	Triple negative (n=79)	P value
Locoregional recurrence	6 (1.6%)	12 (5.6%)	6 (6.8%)	6 (10.2%)	11 (13.9%)	0.001
Local	5 (1.3%)	9 (4.2%)	5 (5.6%)	4 (6.8%)	9 (11.4%)	
Regional	1 (0.3%)	3 (1.4%)	1 (1.1%)	2 (3.4%)	2 (2.5%)	

Table 3: Multivariate analysis for the parameters affecting relapse.

	#Multivariate			
	p	HR	95% CI	
			LL	UL
Age	0.252	0.982	0.953	1.013
T	0.018	4.445	1.291	15.307
N	0.916	161309.4	0	3.3*10 ¹⁰²
Subtype				
Luminal A				
Luminal B	0.002	4.994	1.849	13.489
Luminal b, her2	<0.001	28.188	7.391	107.507
Triple negative	<0.001	315.749	49.324	2021.28
Her2 positive	<0.001	196.807	27.927	1386.93

Her2 82.1 (CI44.62-88.3), in Her2 positive 40.4 (95% CI 31.1-46.2) and in TN 38.5 (95% CI 29.5- 44.3) (Figure. 2).

In univariate analysis, factors significantly predicting LRR were younger age, increasing tumor size, nodal involvement and tumor subtype. In multivariate analysis, independent factors associated with increased LRR were tumor size (p:0.018) and tumor subtypes. Luminal B (p:0.002), luminal B/Her2 (p: 0.001), Her2 positive (p <0.001) and TNBC (p<0.001) were significantly associated with increased risk of LRR, when compared to luminal A subtype (Table 3).

Discussion

Tailoring the systemic therapy and targeted therapy for patients with early breast cancer according to their

molecular subtypes, has achieved significant progress and resulted in improvement in clinical outcomes [14-16]. On the contrary, locoregional treatment decisions still depend only on the clinicopathological criteria as tumor size, nodal status, high histologic grade, lymphovascular invasion and positive margins [17,18].

The potential of consideration of BC molecular subtypes during decision making may improve tailoring locoregional treatment as well as systemic treatment [19]. Quantifying the LRR rate across the different molecular subtypes could be a key factor in optimizing the locoregional control.

Gene expression analysis of BC distinguish distinct molecular subtypes. In this study we did not use these molecular signatures because of unavailability and high cost, instead, we used less expensive immunohistochemistry (IHC) surrogates for major intrinsic biologic Subtypes that have been validated in several trials [11,15]. we investigated the correlation of biological subtype with LRR.

Some studies have reported that the tumor subtype may influence the risk of locoregional recurrences [20-23]. However, other studies found no significant differences between molecular subtypes and locoregional recurrence [24,25].

In this report, the overall risk for locoregional failure was generally low (4.9%) yet it differed significantly across the five biological subtypes.

Higher rates of locoregional- recurrence have been reported in older studies. Voduc et al. identified 10-year rates of locoregional recurrence ranging from 8 % for the luminal A tumors to 13–20 % for other subtypes, in breast cancer patients treated in the period between 1986 and 1992 [7].

The decline in the incidence of LRR reflects the progress in management of breast cancer that have been witnessed over the past two decades whether in the local or systemic therapy.

In our study, luminal A tumors had the lowest rate of LRR compared to other subtypes and the difference was significant. Our result was in accordance with that of Dominici et al. who reported LRR of 1% in luminal A, compared with 6.5% in luminal B, 2% in Her2 positive and 10.9% in TNBC; this difference was significant [26].

Our results compare also with Gabos et al. who found that HER2 positive and TNBC subtypes were associated with the highest rate of loco-regional recurrence [27].

In univariate analysis, we identified larger tumor size, nodal involvement, younger age and tumor subtype as significant predictors of LRR, while in multivariate analysis only tumor size and subtype were the only independent factors.

Braunstein et al. [28] found in a study of 2233 early breast cancer patients that tumor subtypes, age \leq 50 years old and involved axillary LN as predictive factors in univariate analysis.

Most of our patients (76.6%) received systemic chemotherapy; luminal A group was the least to receive chemotherapy (71.2%) while triple negative group had highest rate, where 92.4% received chemotherapy. Adjuvant trastuzumab was given to 24.5 % of Her2 positive patients. Adjuvant hormonal therapy (tamoxifen or aromatase inhibitor or both) was received by 97.7% of the HR positive tumors.

Our study revealed that LRR depends not only on conventional clinicopathologic parameters, but also on tumor biological subtypes. Incorporation of biological subtypes, with clinicopathological factors, into treatment decision making could allow better tailoring of adjuvant radiotherapy treatment based on the risk of LRR [28,29].

Our study has some limitations; being retrospective, classification of tumor subtypes based on IHC-surrogates and not on molecular signature and the low percentage of Her2 positive patients receiving adjuvant trastuzumab (24.5%).

In conclusion, we found that biological subtypes can predict LRR in early breast cancer patients treated by MRM or BCS, this information can aid in deciding the locoregional treatment whether surgery or adjuvant radiation treatment. Tumor subtypes with higher LRR rate may benefit from more aggressive local therapy and closer follow up.

Conflict of interest

The authors declare that they have no conflict of interest.

Funding sources

None.

Acknowledgements

None.

References

- Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, et al. (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. *Journal of clinical oncology* 27: 2466-2473.
- Clarke M, Collins R, Darby S, Davies C, Elphinstone P, et al. (2005) Effects of radiotherapy and differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *The Lancet* 366: 2087-2106.
- Dominici LS, Mittendorf EA, Yu T-K, Bedrosian I (2010) Impact of Breast Cancer Subtypes on Local-Regional Outcomes. *Current Breast Cancer Reports* 2: 107-113
- Fredriksson I, Liljegren G, Palm-Sjovall M, Arnesson LG, Emdin SO, et al. (2003) Risk factors for local recurrence after breast-conserving surgery. *The British journal of surgery* 90: 1093-1102.
- Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, et al. (2016) Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. *Cureus* 8: e924.
- Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. *The Journal of pathology* 220: 263-280.
- Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, et al (2010) Breast cancer subtypes and the risk of local and regional relapse. *Journal of clinical oncology* 28: 1684-1691.
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. *Nature* 406: 747-752.
- Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proceedings of the National Academy of Sciences of the United States of America* 98: 10869-10874.
- Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. *Nature* 490: 61-70.
- Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *Journal of the National Cancer Institute* 101: 736-750.
- Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, et al. (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. *Journal of clinical oncology* 34: 927-935.
- Cossetti RJ, Tyldesley SK, Speers CH, Zheng Y, Gelmon KA (2015) Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. *Journal of clinical oncology* 33: 65-73.
- Gong Y, Liu YR, Ji P, Hu X, Shao ZM (2017) Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. *Sci Rep* 7: 45411.
- Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, et al. (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. *Journal of clinical oncology* 26: 2373-2378.
- Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, et al. (2011) Clinical relevance of TNM staging system according to breast cancer subtypes. *Annals of oncology* 22: 1554-1560.
- Hamamoto Y, Ohsumi S, Aogi K, Shinohara S, Nakajima N, et al. (2014) Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy? *Breast Cancer* 21: 177-82.
- Song YJ, Shin SH, Cho JS, Park MH, Yoon JH, et al. (2011) The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer. *Journal of breast cancer* 14: 198-203.
- Fragomeni SM, Sciallis A, Jeruss JS (2018) Molecular subtypes and local-regional control of breast cancer. *Surgical oncology clinics of North America* 27: 95-120.
- Caudle AS, Yu T-K, Tucker SL, Bedrosian I, Litton JK, et al. (2012) Local-regional control according to surrogate markers of breast cancer

- subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. *Breast cancer research* BCR 14: R83.
21. Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, et al. (2016) Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. *Annals of surgical oncology* 23: 749-756.
22. de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, et al. (2017) Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. *Breast cancer research and treatment* 162: 307-316.
23. Mihalcik SA, Rawal B, Braunstein LZ, Capuco A, Wong JS, et al. (2017) The impact of reexcision and residual disease on local recurrence following breast-conserving therapy. *Annals of surgical oncology* 24: 1868-1873.
24. Millar EKA, Graham PH, O'Toole SA, McNeil CM, Browne L, et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early stage invasive breast cancer using a five-biomarker panel. *Journal of clinical oncology* 27: 4701-4708.
25. Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. *European journal of surgical oncology* 37: 876-882.
26. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, et al. (2012) Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. *Breast cancer research: BCR* 14: R82.
27. Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, et al (2010) The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. *Breast Cancer Res Treat* 124: 187-194.
28. Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, et al. (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast conserving therapy. *Breast cancer research and treatment* 161: 173-179.
29. Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyat F, et al. (2019) Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. *Breast Cancer Research and Treatment* 173: 111-122.